Overview


According to FutureWise analysis the market for antifungal drugs in 2023 is US$ 15.91 billion, and is expected to reach US$ 21.7 billion by 2031 at a CAGR of 4.00%.

Antifungal drugs are medications that are prescribed to treat fungal infections in humans and animals. Fungal infections can occur on the skin, in the lungs, in the digestive system, and in other parts of the body. These infections can vary from mild to severe and can be life-threatening in some cases. Antifungal drugs work by either killing the fungi or preventing their growth and reproduction. Several types of antifungal drugs are available, including topical creams, oral medications, and intravenous (IV) treatments. The type of drug prescribed varies depending on the location and severity of the infection. Topical antifungals are used for skin infections such as athlete's foot and ringworm. Oral antifungals are used for serious infections such as systemic candidiasis and cryptococcal meningitis. IV antifungals are used for severe or life-threatening infections such as invasive aspergillosis and mucormycosis.

Antifungal drugs can have side effects, including nausea, vomiting, diarrhea, and liver damage. It is important to take antifungal medications as prescribed and for the full course of treatment. Stopping treatment too soon can lead to a recurrence of the infection or the development of drug-resistant fungi. In addition, it is important to practice good hygiene to prevent the spread of fungal infections. This includes washing your hands regularly, keeping your skin clean, and avoiding sharing personal belongings such as clothing and towels. In conclusion, antifungal drugs are an important tool in treating fungal infections. With proper use and good hygiene practices, these medications can help to effectively treat and prevent the spread of fungal infections. If you suspect a fungal infection, seeking medical attention in order to acquire an accurate diagnosis and appropriate therapy is important.

FutureWise Market Research has published a report that provides an insightful analysis of Antifungal Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

By the end of the forecast period FutureWise research analysts projects that Antifungal Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • MerckCo., Inc.
  • Novartis International AG
  • Abbott Laboratories
  • Bayer AG
  • Scynexis Inc.
  • Enzon Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Astellas Pharma, Inc.
  • Sigma-Aldrich Corporation
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
  • Kramer Laboratories
  • Basilea Pharmaceutical Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Tecan Group.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antifungal Drugs Market:

  • In June 2021, Posaconazole, a novel triazole antifungal medication from Cadila Pharmaceuticals, was launched to treat a variety of invasive fungal illnesses. Moreover, second-line therapy for Mucormycosis was advised for the medication.

The antifungal drugs market is expected to experience significant growth during the projected timeframe due to a rise in the geriatric population, an increase in the prevalence of fungal infections, and a surge in the number of immunocompromised patients. Fungal infections are a leading contributor to morbidity and mortality worldwide, with an estimated 1.5 billion cases annually. The increasing incidence of fungal infections is driven by factors including the widespread use of antibiotics, the rise in the number of individuals with weakened immune systems, and the growing prevalence of chronic diseases such as HIV/AIDS and cancer. The market is also being influenced by advancements in antifungal drug development, with the introduction of new drug formulations that are more effective and have fewer side effects. Additionally, the availability of over-the-counter antifungal medications contributes to market growth. These drugs are easily accessible to patients and can treat a range of fungal infections, including athlete's foot, ringworm, and jock itch. Another factor driving the growth of the antifungal drugs market is the increasing demand for topical antifungal medications. These drugs are commonly used to treat skin infections and are available in the form of creams, gels, and sprays. The growing popularity of these medications is due to their ease of use and effectiveness in treating a range of fungal infections.  

However, there are also challenges facing the antifungal drugs market. One of the main challenges is the development of drug-resistant fungal infections. This is a growing concern, as many fungal species have developed resistance to commonly used antifungal medications. In addition, the high cost of antifungal drugs is also a significant barrier to market growth, particularly in developing countries where access to healthcare is limited. 

 

By Drug Type

  • Echinocandins
    • Caspofungin
    • Micafungin
    • Anidulafungin
    • Others
  • Azoles
    • Imidazoles
    • Voricanazole
    • Thiazoles
    • Others
  • Polyenes
    • Amphotericin B
    • Candicidin
    • Hamycin
    • Natamycin
    • Others
  • Allylamines
    • Butenafine
    • Terbinafine
    • Naftifine
    • Others

By Infection Type

  • Superficial Antifungal Infections
  • Systemic Antifungal Infections

By Therapeutic Indications

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
    • Invasive Candidiasis
    • Vulvovaginal Candidiasis (VVC)
    • Mouth/Throat/Esophageal Candidiasis
    • Other Candida Infections
  • Others

By Dosage Forms

  • Powders
  • Ointments
  • Drugs
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The U.S. is considered among the world's most economically advanced nations. It presently controls a significant portion of the market. Fungal infections in the United States have posed health officials with difficulties. Resistance to some strains of Candida (a prevalent cause of blood-related infections in the U.S.), according to the Centres for Disease Control and Prevention (CDC), has been observed. The CDC reports that around 7% of all Candida bloodstream tests are not fluconazole-resistant. This viewpoint has been consistent over the last two decades. Furthermore, drug-resistant strains are common in the nation. In addition, the number of elderly persons in the United States is increasing. Despite major breakthroughs in fungal therapy, the incidence and mortality associated with fungal infections have remained practically constant for over a decade. This ongoing degree of fungal proliferation will allow the country's pharmacists to produce an effective and anti-fungal novel, resulting in market growth. Additionally, based on Drug class; the Azoles segment dominated the global market in 2022.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antifungal Drugs Market By Drug Type, By Infection Type, By Therapeutic Indications, By Dosage Forms and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antifungal Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antifungal Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antifungal Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antifungal Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Echinocandins
         1.1. Caspofungin
         1.2. Micafungin
         1.3. Anidulafungin
         1.4. Others
        2. Azoles
         2.1. Imidazoles
         2.2. Voricanazole
         2.3. Thiazoles
         2.4. Others
        3. Polyenes
         3.1. Amphotericin B
         3.2. Candicidin
         3.3. Hamycin
         3.4. Natamycin
         3.5. Others
        4. Allylamines
         4.1. Butenafine
         4.2. Terbinafine
         4.3. Naftifine
         4.4. Others

  • 8.   Antifungal Drugs Market, By Infection Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Superficial Antifungal Infections
        2. Systemic Antifungal Infections

  • 9.   Antifungal Drugs Market, By Therapeutic Indications Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Aspergillosis
        2. Dermatophytosis
        3. Candidiasis
         3.1. Invasive Candidiasis
         3.2. Vulvovaginal Candidiasis (VVC)
         3.3. Mouth/Throat/Esophageal Candidiasis
         3.4. Other Candida Infections
        4. Others

  • 10.   Antifungal Drugs Market, By Dosage Forms Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Powders
        2. Ointments
        3. Drugs
        4. Others

  • 11.   North America Antifungal Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Antifungal Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Antifungal Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Antifungal Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi S.A.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Gilead Sciences, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. MerckCo., Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis International AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott Laboratories
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Scynexis Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Enzon Pharmaceuticals, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline Plc.
         10.1.Company Overview
         10.2.Product Portfolio
         10.3.SWOT Analysis
         10.4.Financial Overview
         10.5.Strategic Overview
        11. Astellas Pharma, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Sigma-Aldrich Corporation
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Agilent Technologies, Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Kramer Laboratories
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Basilea Pharmaceutical Ltd.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Valeant Pharmaceuticals International, Inc.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Tecan Group.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

Related Market

Antifungal Topical Drugs Market

Read More

Antifungal Agents Market

Read More

Antifungal Treatment Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11